CRM
57
2
CB
57
3
XYL
60
-2
DRI
63
3
CAH
43
2
IRM
71
-2
EXC
58
11
HBI
62
7
BIIB
45
-3
OI
39
-4
BXP
52
-2
ORCL
68
3
EOG
49
4
NUE
40
-3
PSA
48
2
ECL
84
2
CMA
52
2
CI
49
3
MRO
50
11
EMC
85
38
CRM
57
2
CB
57
3
XYL
60
-2
DRI
63
3
CAH
43
2
IRM
71
-2
EXC
58
11
HBI
62
7
BIIB
45
-3
OI
39
-4
BXP
52
-2
ORCL
68
3
EOG
49
4
NUE
40
-3
PSA
48
2
ECL
84
2
CMA
52
2
CI
49
3
MRO
50
11
EMC
85
38
Financhill
Back

Accelerate Diagnostics 10K Form

Sell
32

AXDX
Accelerate Diagnostics

Last Price:
0.88
Seasonality Move:
23.72%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AXDX News And Ratings

See the #1 stock for the next 7 days that we like better than AXDX

AXDX Financial Statistics

Sales & Book Value

Annual Sales: $12.06M
Cash Flow: $-8.97M
Price / Cash Flow: 0
Annual Sales: $-1.18
Price / Book: 0

Profitability

EPS (TTM): -4.46000
Net Income (TTM): $-59.05M
Gross Margin: $2.55M
Return on Equity: 0%
Return on Assets: -145.96%

Accelerate Diagnostics Earnings Forecast

Key Accelerate Diagnostics Financial Ratios

  • The Gross Profit Margin over the past 28 years for AXDX is 21.15%.
  • The Selling, General & Administrative Expenses for AXDX have been equal to 258.94% of Gross Profit Margin.
  • The Research & Development expenses have been 210.24% of Revenue.
  • The Interest Expense is -12.57% of Operating Income.
  • The Net Earning history of AXDX is -510.97% of Total Revenues.
  • Per Share Earnings over the last 28 years have been positive in 13 years.

Accelerate Diagnostics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Health Care Equipment & Supplies
Sector: Health Care
Current Symbol: AXDX
CUSIP: 00430H
Website: acceleratediagnostics.com

Debt

Debt-to-Equity Ratio: -1.49
Current Ratio: 1.5
Quick Ratio: 1.11

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

AXDX Technical Analysis vs Fundamental Analysis

Sell
32
Accelerate Diagnostics (AXDX) is a Sell

Is Accelerate Diagnostics a Buy or a Sell?